Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Y0001437

Nateglinide

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Fastic, N-[(trans-4-Isopropylcyclohexyl)carbonyl]-D-phenylalanine, Starlix, Starsis

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C19H27NO3
CAS Number:
105816-04-4
Molecular Weight:
317.42
MDL number:
MFCD00875706
UNSPSC Code:
41116107
PubChem Substance ID:
329831425
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

nateglinide

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CC(C)[C@@H]1CC[C@H](CC1)C(=O)N[C@H](Cc2ccccc2)C(O)=O

InChI

1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1

InChI key

OELFLUMRDSZNSF-BRWVUGGUSA-N

Gene Information

human ... ABCC8(6833) , KCNJ11(3767)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Nateglinide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Nateglinide is a Kir6.2/SUR1 channel inhibitor and antidiabetic. It is selective for the SUR1 subtype, which is found on pancreatic islet cells. Nateglinide evokes KATP channel-dependent insulin secretion (50-200 μM) in the absence and presence of insulin.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

George Grunberger
Expert opinion on pharmacotherapy, 12(13), 2097-2106 (2011-08-02)
It has been hypothesized that reducing postprandial glucose spikes would result both in improved overall glycemic control and long-term (especially cardiovascular) outcomes in patients with type 2 diabetes. Nateglinide, a short-acting insulin secretagogue of the meglitinide class of antidiabetic agents
Nicholas Tentolouris et al.
Vascular health and risk management, 3(6), 797-807 (2008-01-19)
Impaired insulin secretion occurs early in the pathogenesis of type 2 diabetes mellitus (T2DM) and is chronic and progressive, resulting initially in impaired glucose tolerance (IGT) and eventually in T2DM. As most patients with T2DM have both insulin resistance and
Nateglinide, a new agent for postprandial glucose control in type 2 diabetes.
Srividya Kotapati
Connecticut medicine, 66(5), 269-272 (2002-06-20)
C J Dunn et al.
Drugs, 60(3), 607-615 (2000-10-13)
Nateglinide is a novel D-phenylalanine derivative that inhibits ATP-sensitive K+ channels in pancreatic beta-cells in the presence of glucose and thereby stimulates the prandial release of insulin. Nateglinide reduces fasting and mealtime blood glucose levels in animals, healthy volunteers, and
Marc K Israel et al.
Vascular health and risk management, 4(6), 1167-1178 (2008-01-01)
The increasing prevalence of type 2 diabetes provides impetus for both development of new drugs to improve glycemic control and for reconsideration of treatment strategies with existing agents. Combination therapy with complementary drug classes that act on different aspects of
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service